New animal research suggests that the antiviral drug remdesivir – a cornerstone of COVID‑19 therapy – may aggravate acute kidney injury (AKI) by disrupting mitochondrial function and triggering cell‑death pathways. The study, carried out in rats with experimentally induced kidney ischemia‑reperfusion (I/R) injury, found that a single dose of remdesivir (25 mg/kg) reduced the mitochondrial biogenesis marker PGC‑1α and boosted the pro‑apoptotic protein caspase‑3, especially when delivered subcutaneously. Oxidative stress markers as well rose, while antioxidant defenses fell, pointing to a potential “double‑hit” on vulnerable kidneys.
AKI is a frequent and serious complication of severe COVID‑19, affecting up to 30 % of hospitalized patients and worsening outcomes 【1†https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/】. Remdesivir (GS‑5734) has been shown to shorten recovery time and lower viral loads 【2†https://www.fda.gov/media/143387/download】, but its safety profile in patients with pre‑existing renal impairment remains debated. Pharmacokinetic data indicate that roughly 74 % of the drug and its metabolites are cleared by the kidneys 【3†https://pubmed.ncbi.nlm.nih.gov/32813102/】, raising concerns about accumulation and toxicity in this population.
Study design and key findings
Researchers divided 24 adult male Wistar rats into four groups: a sham control, an I/R‑injury group, and two I/R groups pre‑treated with remdesivir either intraperitoneally (IP) or subcutaneously (SC). One hour before inducing 45 minutes of left‑kidney ischemia, the animals received a single 25 mg/kg dose of remdesivir. Six hours after reperfusion, blood and kidney tissue were harvested for biochemical, histological and molecular analyses.
The main observations were:
- PGC‑1α (mitochondrial biogenesis): Levels fell by ~30 % in the SC‑treated group compared with I/R alone (p ≤ 0.04), indicating impaired mitochondrial regeneration.
- Caspase‑3 (apoptosis): A four‑fold increase was recorded in the SC‑treated rats (p = 0.003), suggesting heightened renal cell death.
- Oxidative stress (MDA): Malondialdehyde rose significantly in the SC group (p = 0.016), reflecting lipid peroxidation.
- Antioxidant capacity (GPX, TAC): Glutathione peroxidase activity and total antioxidant capacity dropped (p = 0.003 and p = 0.045, respectively), weakening the kidney’s defense against free radicals.
- Inflammation (NF‑κB) and mitochondrial dynamics (Drp‑1): No meaningful changes were detected, indicating that the observed damage was not driven by overt inflammatory signaling.
Serum creatinine and urea – standard markers of renal function – did not differ significantly among the groups, and histological scoring showed only modest, non‑significant differences. This suggests that molecular injury may precede measurable functional decline within the early 6‑hour window.
How the findings fit with clinical data
Reports of remdesivir‑associated AKI have emerged from pharmacovigilance databases. A WHO safety‑signal analysis flagged an excess of acute renal failure reports linked to the drug 【4†https://doi.org/10.1002/cpt.2145】, while a U.S. FDA adverse‑event review noted a higher incidence of AKI in patients with baseline glomerular filtration rates (GFR) < 30 mL/min 【5†https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-remdesivir-use-patients-covid-19】. Conversely, several cohort studies have found no statistically significant rise in AKI among patients receiving remdesivir, even in those with moderate renal dysfunction 【6†https://pubmed.ncbi.nlm.nih.gov/34027431/】, and a recent meta‑analysis of 3,095 participants concluded that remdesivir does not increase the overall risk of AKI 【7†https://doi.org/10.1016/j.clinsp.2023.100200】.
The animal data add a mechanistic layer to this debate. By demonstrating that remdesivir can suppress PGC‑1α‑driven mitochondrial renewal and activate caspase‑3, the study offers a plausible pathway for renal injury that might be amplified in patients whose kidneys are already compromised or hypoxic – a common scenario in severe COVID‑19.
Clinical implications and next steps
Given the drug’s predominant renal clearance, clinicians have been advised to exercise caution when prescribing remdesivir to patients with an estimated GFR < 30 mL/min or those on dialysis 【8†https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/】. The new findings reinforce the need for:
- Close monitoring of renal biomarkers (creatinine, cystatin‑C) before and during therapy, especially in high‑risk groups.
- Consideration of alternative antivirals or dose adjustments when renal function is borderline.
- Further clinical studies that track early molecular markers (e.g., PGC‑1α expression in urinary exosomes) alongside traditional labs.
Future research should also explore whether the route of administration influences renal safety – the rat study hinted that subcutaneous delivery might be more harmful than intraperitoneal injection. Human pharmacokinetic data comparing intravenous versus subcutaneous routes could clarify this point.
At a glance – molecular changes observed in the rat model
| Marker | Direction of change | Implication |
|---|---|---|
| PGC‑1α (mitochondrial biogenesis) | ↓ (significant) | Impaired mitochondrial renewal |
| Drp‑1 (mitochondrial fission) | No significant change | Fission unchanged |
| Caspase‑3 (apoptosis) | ↑ (4‑fold in SC group) | Increased renal cell death |
| MDA (oxidative stress) | ↑ (significant) | Lipid peroxidation |
| GPX (antioxidant enzyme) | ↓ (significant) | Reduced antioxidant defense |
| TAC (total antioxidant capacity) | ↓ (significant) | Lower overall antioxidant reserve |
| NF‑κB (inflammation) | No significant change | Inflammatory signaling not primary driver |
While the study’s short observation window (6 hours) limits conclusions about long‑term kidney outcomes, the molecular signals align with known pathways of ischemic injury and suggest that remdesivir could tip the balance toward damage in an already stressed kidney.
Disclaimer: This article provides general information and does not constitute medical advice. Always consult a qualified health professional before making decisions about treatment.
We welcome your thoughts on the safety of remdesivir in patients with kidney disease. Share your comments below and spread the word to preserve the conversation going.
